Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Healthy men and women aged 18 to 45 years written informed consent consent to use of effective contraception methods during the whole period of participation in the study; (using one of the following methods: abstinence, condoms (male or female with or without spermicide), diaphragm or cervical cap with a spermicidal tool, intrauterine device) body mass index (BMI) is 18.5 ≤ BMI ≤ 30 absence of acute infections/exacerbations of chronic at the time of participation in the study and for 7 days before initiation of therapy absence of allergic disease severe disease (anaphylaxis, angioedema, polymorphic exudative eczema, serum sickness) no history of severe complications in a previous application of immunobiological preparations lack of history, but also according to screening tests, pathology of the gastrointestinal tract, liver, kidneys, cardiovascular system, Central nervous system, musculoskeletal, urogenital and endocrine systems that can influence the evaluation of the results of the study negative pregnancy test blood or urine (for women of childbearing age) not more than 24 hours before receiving the first dose of study drug negative tests for HIV, hepatitis b and C, syphilis  volunteer participation in any other clinical trial within the last 90 days respiratory symptoms in the last 3 days treatment with steroids for the last 10 days (excluding preparations for intranasal administration and topical application) allergic reactions to proteins/epithelium of the mouse in history or about the results of laboratory studies on the screening, the titer of anti-mouse antibodies according to the study of 1:500 and more; introduction immunoglobulins or other blood products within the last 6 months treatment with immunosuppressive drugs and/or immunomodulators within 6 months prior to the study the use of other drugs based on murine monoclonal antibodies in history regular past or current use of narcotic drugs pregnancy or breast-feeding systolic blood pressure less than 100 mm of mercury.St. or above 139 mm Hg.St; diastolic blood pressure less than 60 mm of mercury.St. or higher 90 mm. Hg.St.; heart rate less than 60 beats/min or more than 90 beats/min aggravation of allergic diseases, the presence of anaphylactic reactions or angioedema in history